Moderators: Michael Bookman, MD and Bhavana Pothuri, MD

Presentations:

• (LBA) Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC): A Subgroup Analysis of ENGOT-ov60/GOG-3052/RAMP 201 Part A (Susana N. Banerjee, MBBS, MA, PhD FRCP)
• (LBA) UPLIFT (ENGOT-ov67/GOG-3048): Results from the Phase 2 trial of Upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-Directed Dolaflexin Antibody-Drug Conjugate (ADC) in Platinum-Resistant Ovarian Cancer (PROC) (Debra L. Richardson, MD)
• (LBA) A phase II study of tazemetostat, (EPZ-6438) in recurrent or persistent endometrioid or clear cell carcinoma of the ovary, and recurrent or persistent endometrioid endometrial adenocarcinoma: Results from the NRG GY014 Trial (Alison Schram, MD)
• Distillation: Kathleen Moore, MD
• (LBA) Refining Ovarian Cancer Test Accuracy Scores: A multicentre, prospective cohort study investigating diagnostic accuracy in women with symptoms of suspected ovarian cancer (The ROCkeTS Study): results for post-menopausal women (Sudha Sundar, MBBS, MPhil, MRCOG)
• (LBA) Evaluation of Physical Function and Quality of Life (Qol) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) For Stage IA1 (LVSI+) and IA2-IB1 (GOG#278). Funded by NCI/NCORP (NCT01649089) (Allan Covens, MD, FRCSC)
• (LBA) Evaluation Efficacy and Fertility After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) For Stage IA1 (LVSI+) and IA2-IB1 (GOG278) cervical cancer Funded by NCI/NCORP (NCT01649089) (Allan Covens, MD, FRCSC)
• (LBA) APL-1702 long-term efficacy and safety for cervical histologic high-grade squamous intraepithelial lesions (HSIL): results from a randomized phase 3 global study (Yue Wang, MD)
• Late Breaking Abstract Distillation on the Latest Advancements in Gynecologic Oncology (Kristen Bixel, MD)